

Curriculum Vitae

DR. Dario Sangiolo

Personal information

Date of Birth: 03/07/1973, Milazzo (ME)

Work address: Cattedra di Oncologia Medica

Istituto per la Ricerca e la Cura del Cancro
Strada Provinciale 142, 10060 Candiolo (TO)
Tel. 011.9933628 - Fax 011.9933299.
e-mail: dario.sangiolo@ircc.it

Academic Education

- **2004-2008**
PhD in Human Oncology
University of Torino, Department of Oncological Sciences
 - **1999 – 2003**
Medical Specialization in Clinical Oncology
University of Torino Medical School
Grade: 70/70
 - **1992 – 1998**
6 years University Degree in Medicine
University of Messina, Medical School
Grade: 110/100 cum laude
-

Employment and research experience

- **07/2012 to date Assistant professor,**
 Department of Oncology,
 University of Torino,
 Group leader, Laboratory Cell therapy of Cancer
 Institute for Cancer Research and Treatment Candiolo (Torino), Italy
 Main activities: Coordination of preclinical research projects on cancer immunotherapy
- **10/2006 – 07/2012**
Research Associate, group leader
 University of Torino, Institute for Cancer Research and Treatment, Candiolo (Torino), Italy.
 Department of Oncology
 Main activities: Coordination of preclinical research projects on cancer immunotherapy with CIK cells and transplant immunology.
- **06/2002 to 08/2004 and 09/2005 to 09/2006**
Postdoctoral Research Fellow
 Fred Hutchinson Cancer Research Center, University of Washington (Seattle – WA, U.S.A).
 Transplant Biology Department, (*Prof. Rainer Storb, Prof. George Georges*).
 Main activities: Coordination of preclinical research projects of transplant immunology and cell therapy.
 Coordination of a Clinical research project on Hemopoietic Stem Cell transplant for the treatment of Severe Aplastic Anemia
- **09/2004 – 08/2005**
Assegnista di Ricerca (Research Associate, group leader)
 University of Torino, Institute for Cancer Research and Treatment, provinciale 142, 10060 Candiolo (Torino), Italy.
 Department of Oncological Sciences
 Main activities: Coordination of preclinical research projects on cancer immunotherapy with CIK cells and gene-modified T lymphocytes.
- **01/1999 – 06/2002**
Research Fellow
 University of Torino, Institute for Cancer Research and Treatment, provinciale 142, 10060 Candiolo (Torino), Italy.
 Department of Oncological Sciences
 Main activities: Work on preclinical research projects in the setting of metastatic Osteosarcoma.

Clinical experiences

- **09/2004 – 08/2005 and 10/2006 to date**
Medical oncologist
 Institute for Cancer Research and Treatment, provinciale 142, 10060 Candiolo (Torino), Italy.
 Oncology-Hematology Clinical Division

Main activities: *Clinical work in the outpatient service. In charge of patients affected by solid and hematologic tumors, especially sarcomas and melanoma. Direct participation in clinical research trials.*

- **11/1999- 06/2002:**

Residency in medical Oncology

University of Torino, Institute for Cancer Research and Treatment, provinciale 142, 10060 Candiolo (Torino), Italy.

Department of Oncological Sciences

- **02/1999 - 11/1999:**

Clinical fellow,

Institute for Cancer Research and Treatment, provincial 142, 10060 Candiolo (Torino), Italy.
Oncology-Hematology Clinical Division

PERSONAL SKILLS AND COMPETENCES

Experience and competence with all the main techniques of cell biology, primary cell cultures, Immunology, Flow Cytometry, molecular biology, cloning and gene-transfer..

Organizational skills and competences

- Experience and competence in the design and coordination of preclinical research projects of adoptive immunotherapy and transplant immunology. Coordination and mentoring of 2 PhD students and 1 post Doctoral Fellow.

Mother Tongue

- Italian

Other Languages

- English
 - *Reading Skills:* Excellent
 - *Writing Skills:* Excellent
 - *Verbal Skills:* Excellent

MEMBERSHIPS

Member of the Italian Society of Medical Oncology

Member of American Society of Hematology

Member of the Italian Network for Tumor Biotherapies (NIBIT)

Editorial Board Member of Scientific Journal: *Expert Opinion on Biological Therapy*

Invited lectures to international conferences

- 40th EBMT (European Bone Marrow Transplantation) meeting
02/04/13, Milan, Italy
Educational Lecture:

"CIK cells as adoptive immunotherapy for solid tumors"

- EBMT Solid Tumours Working Party Meeting.
10/11/2011, Brescia, Italy.
"Immunotherapy with CIK cells for solid Tumors".
- 4th ATST (Autologous and Allogeneic Cell Therapy in Solid Tumors) Meeting.
31/03/2011, Venice, Italy.
"CIK therapy for solid tumors".
- VII NIBIT (Network Italiano Bioterapie dei Tumori) Meeting
02/10/09, Siena, Italy
"CIK cells as adoptive immunotherapy for solid tumors: preclinical data and potential clinical applications".
- 3rd ATST (Allogeneic Transplantation for Solid Tumors) Meeting.
27/03/08, Siena, Italy.
"Directing donor T-cells against CEA and survivin after transplantation to augment GVT"
- 2007 ASBMT Meeting.
09/02/07, Keystone (CO), USA.
"Redirecting GVT after Allografting in Colorectal Cancer: Active Vaccination and Adoptive Immunotherapy".

Publications

1. Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, Caravelli D, Giaccone E, Venesio T, Balsamo A, Pignochino Y, Grignani G, Carnevale-Schianca F, Aglietta M, **Sangiolo D**. [Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features.](#) Clin Cancer Res. 2013 Aug 15;19(16):4347-58
2. Milani A, **Sangiolo D**, Montemurro F, Aglietta M, Valabrega G. [Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.](#) Ann Oncol. 2013 Jul;24(7):1740-8
3. Pignochino Y, Dell'aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, **Sangiolo D**, Torchiario E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G. [The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models.](#) Clin Cancer Res. 2013 Apr 15;19(8):2117-2131.
4. Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR, Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, **Sangiolo D**. [Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers.](#) J Immunother. 2012 Sep;35(7):579-586
5. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, **Sangiolo D**.

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Expert Opin Biol Ther. 2012 Jun;12(6):673-84..

6. Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M, Jordaney N, Circosta P, Elia A, Lesnikova M, Georges GE, Piacibello W, Fagioli F, Cignetti A, Aglietta M, **Sangiolo D**. Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. J Biotechnol. 2011 Dec 10;156(3):218-26.
7. **Sangiolo D**. Cytokine induced killer cells as promising immunotherapy for solid tumors. *J Cancer*. 2011;2:363-8.
8. Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, **Sangiolo D**, Fizzotti M, Caravelli D, Capaldi A, Anselmetti G, Palesandro E, D'Ambrosio L, Coha V, Obert R, Aglietta M, Grignani G. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol. 2011 Aug 20;29(24):e691-3.
9. **Sangiolo D**, Leuci V, Gallo S, Aglietta M, Piacibello W. Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. Expert Opin Biol Ther. 2011 May;11(5):655-66.
10. **Sangiolo D**, Storb R, Deeg HJ, Flowers ME, Martin PJ, Sandmaier BM, Kiem HP, Nash RA, Doney K, Leisenring WM, Georges GE. Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant. 2010 Oct;16(10):1411-8.
11. Leuci V, Gammaitoni L, Capellero S, **Sangiolo D**, Mesuraca M, Bond HM, Migliardi G, Cammarata C, Aglietta M, Morrone G, Piacibello W. Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene. Stem Cells. 2009 Nov;27(11):2815-23.
12. Circosta P, Granziero L, Follenzi A, Vigna E, Stella S, Vallario A, Elia AR, Gammaitoni L, Vitaggio K, Orso F, Geuna M, **Sangiolo D**, Todorovic M, Giachino C, Cignetti A. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum Gene Ther. 2009 Dec;20(12):1576-88.
13. **Sangiolo D**, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther. 2009 Jul;9(7):831-40.
14. **Sangiolo D**, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008 Jul;20(7):841-8.
15. **Sangiolo D**, Lesnikova M, Nash RA, Jensen MC, Nikitine A, Kiem HP, Georges GE. Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther. 2007 Nov;14(21):1549-54.
16. Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A, Sperti E, Ferraris R, Gatti M, Grignani G, Rota-Scalabrini D, Geuna M, Fizzotti M, **Sangiolo D**, Sottile A, De Rosa G, Bucci AR, Lambertenghi-Delilieri G, Benedetti E, Nash R, Aglietta M.

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.
Blood. 2006 May 1;107(9):3795-803.

17. **Sangiolo D**, Storer B, Nash R, Corey L, Davis C, Flowers M, Hackman RC, Boeckh M.
Toxicity and efficacy of daily dapsone as *Pneumocystis jiroveci* prophylaxis after hematopoietic stem cell transplantation: a case-control study.
Biol Blood Marrow Transplant. 2005 Jul;11(7):521-9.
18. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, **Sangiolo D**, Bussolino F, Piacibello W, Aglietta M.
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7.